Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease

Digestive and Liver Disease

Volumn 43, Issue SUPPL. 1, 2011, Pages

  Morisco, Filomena ^a   Castiglione, Fabiana ^a   Rispo, Antonio ^a   Stroffolini, Tommaso ^b   Vitale, Roberto ^a   Sansone, Stefano ^a   Granata, Rocco ^a   Orlando, Ambrogio ^c   Marmo, Riccardo ^d   Riegler, Gabriele ^e   Vecchi, Maurizio ^f   Biancone, Livia ^g   Caporaso, Nicola ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d Gastroenterology Unit   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Antivirals; Biological agents; HBV reactivation; Prophylaxis

Indexed keywords

ADALIMUMAB; ADEFOVIR; AZATHIOPRINE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; DEFLAZACORT; ENTECAVIR; INFLIXIMAB; LAMIVUDINE; MERCAPTOPURINE; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; PREDNISONE; STEROID; TACROLIMUS; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIVIRAL THERAPY; ARTICLE; CROHN DISEASE; ENTERITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MONITORING; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; SCREENING; SYSTEMATIC REVIEW; TRANSPLANTATION; ULCERATIVE COLITIS; VACCINATION; VIRUS INFECTION; VIRUS REACTIVATION;

ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; PREVALENCE; VIRUS ACTIVATION;

EID: 78650657357     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(10)60691-3     Document Type: Article

References (72)

1. Laskus T, Slusarczyk J, Cianciare J, et al. Exacerbation of chronic active hepatitis B after short-term corticosteroid therapy resulting in fatal liver failure. Am J Gastroenterol 1990, 85:1414-1417.
2. Lau GK, He ML, Fong DY, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hemotopoietic cell transplantation. Hepatology 2002, 36:702-709.
3. Law JK, Ho JK, Hoskins PJ, et al. Fatal reactivation of hepatitis B postchemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma 2005, 46:1085-1089.
4. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008, 148:519-528.
5. Mindikoglu AL, Regev A, Schifi ER Hepatitis B reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastro Hepatol 2006, 4:1076-1081.
6. Tillmann HL, Wedemeyer H, Manna MP Treatment of hepatitis B in special patient groups: hemodialysis, heart and renal transplant, fulminant hepatitis, hepatitis B reactivation. J Hepatol 2003, 39:5206-5211.
7. Yeo W, Johnson PJ Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006, 43:209-220.
8. Biancone L, Pavia M, Del Vecchio Blanco G, Italian Group for the Study of the Colon and Rectum (GISC), et al. Hepatitis B and C virus infection in Crohn's disease. Inflamm Bowel Dis 2001, 7:287-294.
9. Biancone L, Del Vecchio Blanco G, Pallone F, Italian Group for the Study of the Colon and Rectum, et al. Immunomodulatory drugs in Crohn's disease patients with hepatitis B or C virus infection. Gastroenterology 2002, 122:593-594.
10. Colbert C, Chavarria A, Berkelhammer C Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm Bowel Dis 2007, 13:1453-1454.
11. Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003, 30:1624-1625.
12. Millonig G, Kern M, Ludwiczek O, et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening?. World J Gastroenterol 2006, 12:974-976.
13. Madonia S, Orlando A, Scimeca D, et al. Occult hepatitis B and infliximab induced HBV reactivation. Inflamm Bowel Dis 2007, 13:508-509.
14. Kohrt HE, Ouyang DL, Keefe ED Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006, 24:1003-1016.
15. Liu CJ, Lai MY, Lee PH, et al. Lamivudine treatment for hepatitis B reactivation in HBsAg carrier after organ transplantation: a 4-year experience. J Gastroenterol Hepatol 2001, 16:1001-1008.
16. Travis SP Which 5-ASA?. Gut 2002, 51:548-549.
17. Travis S, Stange EF, Lémann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis 2008, 2:24-62.
18. Prefontaine E, Macdonald JK, Sutherland LR, et al. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009 Oct 7.
19. Ardizzone S, Maconi G, Russo, et al. A randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55:47-53.
20. Alfadhli AA, McDonald JW, Feagan BG, et al. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2005 Jan 25.
21. Patel V, Macdonald JK, McDonald JW, et al. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009 Oct 7.
22. Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003, 125:380-388.
23. Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999, 117:761-769.
24. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001, 121:1088-1094.
25. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007, 357:239-250.
26. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226-1231.
27. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
28. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009, 58:501-508.
29. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
30. Lémann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130:1054-1061.
31. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
32. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002, 359:1541-1549.
33. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868.
34. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009, 15:1295-1301.
35. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
36. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2006, 354:2200.
37. Järnerot G, Hertervig E, Friis-Liby I Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005, 128:1805-1811.
38. Kohn A, Daperno M, Armuzzi A Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007, 26:747-756.
39. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006, 130:323-333.
40. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
41. Feagan BG, Panaccione R, Sandborn WJ Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008, 135:1493-1499.
42. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
43. Van Assche G, Vermeire S, Rutgeerts P The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol 2010, 7:79-85.
44. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2482.
45. Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009, 7:874-881.
46. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008, 6:644-653.
47. Perrillo RP Acute flares in chronic hepatitis B: The natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001, 120:1009-1022.
48. Herbein G, O'Brien WA Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 2000, 223:241-257.
49. Kasahara S, Ando K, Saito K, et al. Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol 2003, 77:2469-2476.
50. Marzano A, Angelucci E, Andreone P, Italian Association for the Study of the Liver, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007, 39:397-408.
51. Institut de Veille Sanitaire Prévalence des hépatites B et C en France en 2004. Saint-Maurice 2007, Institut de Veille Sanitaire, France.
52. Chevaux JB, Nani A, Oussalah A, et al. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm Bowel Dis 2010, 16:916-924.
53. Di Stefano R, Stroffolini T, Ferraro D, et al. Endemic hepatitis C virus infection in a Sicilian town: further evidence for iatrogenic transmission. J Med Virol 2002, 67:339-344.
54. Pendino GM, Mariano A, Surace P, et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology 2005, 41:1151-1159.
55. Salleras L, Domínguez A, Bruguera M, et al. Declining prevalence of hepatitis B virus infection in Catalonia (Spain) 12 years after the introduction of universal vaccination. Vaccine 2007, 25:8726-8731.
56. Stroffolini T, Menchinelli M, Taliani G, et al. High prevalence of hepatitis C virus infection in a small central Italian town: lack of evidence of parenteral exposure. Gastroenterol 1995, 27:235-238.
57. Stroffolini T, Guadagnino V, Chionne P, et al. A population based survey of hepatitis B virus infection in a Southern Italian town. Ital J Gastroenterology Hepatol 1997, 29:415-419.
58. Stroffolini T, Bianco E, Szklo A, et al. Factors affecting the compliance of the antenatal hepatitis B screening programme in Italy. Vaccine 2003, 7:1246-1249.
59. Stroffolini T, Almasio PL, Sagnelli E, et al. Evolving Clinical Landscape of Chronic Hepatitis multicenter Italian Study. J Med Virol 2009, 81:1999-2006.
60. Loras C, Saro C, Gonzalez-Huix F, et al. Prevalence and factors related to hepatitis B and C in inflammatory bowel disease patients in Spain: a nationwide, multicenter study. Am J Gastroenterol 2009, 104:57-63.
61. Tolentino YF, Fogaca HS, Zaltman C, et al. Hepatitis B virus prevalence and transmission risk factors in inflammatory bowel disease patients at Clementino Fraga Filho University Hospital. World J Gastroenterol 2008, 14:3201-3206.
62. Zeitz J, Mullhaupt B, Fruehauf H, et al. Hepatic failure due to hepatitis B reactivation in a patient with ulcerative colitis treated with prednisone. Hepatology 2009, 50:653-654.
63. del Valle Garcia-Sanchez M, Gomez-Camacho F, Poyato-Gonzalez A, et al. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004, 10:701-702.
64. Esteve M, Loras C, Gonzalez-Huix F Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm Bowel Dis 2007, 13:1450-1451.
65. Ojiro K, Naganuma M, Ebinuma H, et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008, 43:397-401.
66. Ueno Y, Tanaka S, Shimamoto M, et al. Infliximab therapy for Crohn's disease in a patient with chronic hepatitis B. Dig Dis Sci 2005, 50:163-166.
67. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004, 53:1363-1365.
68. Loras C, Gisbert JP, Mínguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010, 59:1340-1346.
69. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis 2009, 10.1016/j.crohns.2009.02.010.
70. Nardone A, Anastassopoulou CG, Theeten H, et al. A comparison of hepatitis B seroepidemiology in ten European countries. Epidemiol Infect 2009, 137:961-969.
71. Lok ASF, McMahon BJ Chronic hepatitis B. Practice guidelines. Hepatology 2007, 45:507-539.
72. European Association for the Study of the Liver (EASL) EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009, 50:227-242.